{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"5","value":"1.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"2","value":"0.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"6","value":"2.0"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"2","value":"1.0"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"6","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"10"}],"units":"Participants"}],"description":"The maximum duration for which a participant continuously maintained a platelet count \\>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count","dispersionType":"Full Range","groups":[{"description":"Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.","id":"OG000","title":"Part 2 (Randomized Period) Cohort 1-Placebo"},{"description":"Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG001","title":"Part 2 (Randomized Period) Cohort 1- Eltrombopag"},{"description":"Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.","id":"OG002","title":"Part 2 (Randomized Period) Cohort 2-Placebo"},{"description":"Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \\<27 kg received 25 mg QD and participants with a weight of \\>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \\<27 kg received 12.5 mg QD and participants with a weight of \\>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG003","title":"Part 2 (Randomized Period) Cohort 2-Eltrombopag"},{"description":"Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.","id":"OG004","title":"Part 2 (Randomized Period) Cohort 3-Placebo"},{"description":"Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG005","title":"Part 2 (Randomized Period) Cohort 3- Eltrombopag"}],"paramType":"MEDIAN","populationDescription":"ITT Population, only those participants enrolled in Part 2 were analyzed. The number of participants used to compute the summary statistics reflect the ITT poplation through out the analyses during Part 2.","reportingStatus":"POSTED","timeFrame":"From Baseline through Week 7 of Part 2","title":"Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2","type":"SECONDARY","unitOfMeasure":"Weeks"}